US EditionFew Babies Getting RSV Antibody Shot, Study Says
SOUTH AFRICA, JUL 16 – The vaccine reduces severe RSV risk in infants by 82.4% within 90 days, with the National Advisory Group recommending its inclusion in the public immunisation program.
- Researchers reported in 2024 that about one-third of more than 7,200 babies eligible under the FDA-approved antibody nirsevimab received it in Pennsylvania and New Jersey.
- The low uptake stemmed from nirsevimab’s recent 2023 approval, uncertainty about insurance coverage, and early hesitancy despite CDC recommendations for infants under eight months.
- Significant racial and socioeconomic disparities appeared, with Black babies 47% less likely, poor children 30% less likely, and Medicaid-enrolled children 21% less likely to receive the antibody.
- Beyfortus reduced hospitalization risk by 80%, and the maternal RSV vaccine Abrysvo decreased infant hospitalization by 72%, according to recent studies.
- These findings highlight the need for improved outreach, education, and equitable access to RSV prevention measures worldwide, especially for vulnerable populations.
Insights by Ground AI
Does this summary seem wrong?
15 Articles
15 Articles
Coverage Details
Total News Sources15
Leaning Left3Leaning Right3Center3Last UpdatedBias Distribution33% Left, 33% Center, 33% Right
Bias Distribution
- 33% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
33% Right
L 33%
C 33%
R 33%
Factuality
To view factuality data please Upgrade to Premium
